AbCellera Biologics (ABCL) Short term Debt (2020 - 2025)

AbCellera Biologics has reported Short term Debt for 6 years, with the latest figure at $8.8 million in Q1 2025.

• For the quarter ending Q1 2025, Short term Debt fell 82.95% year-over-year to $8.8 million; the trailing twelve-month figure through Mar 2025 stood at $8.8 million (down 82.95% YoY), and the FY2024 full-year result was $8.1 million, down 83.98% from the prior year.
• Short term Debt for Q1 2025 stood at $8.8 million, up from $8.1 million in the prior quarter.
• The five-year high for Short term Debt was $54.9 million in Q2 2023, with the low at $8.1 million in Q4 2024.
• Historically, Short term Debt has averaged $30.0 million across 5 years, with a median of $27.5 million in 2022.
• Annual changes were most pronounced in 2022 — Short term Debt soared 195.99% — and 2024, when it slumped 83.98%.
• AbCellera Biologics' Short term Debt stood at $22.9 million in 2021, then jumped by 92.77% to $44.2 million in 2022, then advanced by 14.17% to $50.5 million in 2023, then tumbled by 83.98% to $8.1 million in 2024, then climbed by 8.46% to $8.8 million in 2025.
• The last three Short term Debt figures came in at $8.8 million (Q1 2025), $8.1 million (Q4 2024), and $20.2 million (Q3 2024), per Business Quant data.